Overview
flowchart TD
companies_id_pharma["ID Pharma Co., Ltd."]
style companies_id_pharma fill:#4fc3f7,stroke:#333,color:#000
companies_id_pharma_0["Technology Platform"]
companies_id_pharma -->|"includes"| companies_id_pharma_0
style companies_id_pharma_0 fill:#81c784,stroke:#333,color:#000
companies_id_pharma_1["AAV Vector Development"]
companies_id_pharma -->|"includes"| companies_id_pharma_1
style companies_id_pharma_1 fill:#ef5350,stroke:#333,color:#000
companies_id_pharma_2["Blood-Brain Barrier Crossing Technology"]
companies_id_pharma -->|"includes"| companies_id_pharma_2
style companies_id_pharma_2 fill:#ffd54f,stroke:#333,color:#000
companies_id_pharma_3["Lentiviral Vector Production"]
companies_id_pharma -->|"includes"| companies_id_pharma_3
style companies_id_pharma_3 fill:#ce93d8,stroke:#333,color:#000
companies_id_pharma_4["Neurodegeneration Programs"]
companies_id_pharma -->|"includes"| companies_id_pharma_4
style companies_id_pharma_4 fill:#4fc3f7,stroke:#333,color:#000
companies_id_pharma_5["Parkinsons Disease Programs"]
companies_id_pharma -->|"includes"| companies_id_pharma_5
style companies_id_pharma_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
ID Pharma Co., Ltd. (株式会社アイディーファーマ) is a Japanese biotechnology company headquartered in Tokyo, specializing in gene therapy and viral vector technology for neurological disease applications. Founded in 2003, ID Pharma has established itself as one of Japan's leading providers of adeno-associated virus (AAV) vectors and lentiviral vectors for research, preclinical, and clinical applications["@idpharma_co"].
The company operates at the intersection of Japan's strengths in viral vector research and the growing global demand for gene therapy delivery systems. With neurodegenerative diseases representing a major unmet medical need, ID Pharma has focused its development efforts on creating vector systems capable of effectively delivering therapeutic genes to the brain and central nervous system.
ID Pharma's core technology platform centers on three key capabilities:
AAV Vector Development
The company produces high-titer, high-purity AAV vectors with enhanced tissue specificity. ID Pharma has developed proprietary cell lines and production methods that increase vector yield while maintaining the safety and purity standards required for clinical use[@aav_neuro]. Their AAV serotype library includes:
- AAV9: Strong CNS tropism, crosses the [blood-brain barrier](/entities/blood-brain-barrier) more efficiently than older serotypes
- AAVrh10: Enhanced midbrain targeting for Parkinson's disease applications
- AAVrh74: Novel serotype with high transduction efficiency in primate brain tissue
Blood-Brain Barrier Crossing Technology
A key focus of ID Pharma's research involves engineering viral vectors that can effectively cross the blood-brain barrier[@bbb_trans]. Strategies under development include:
- Capsid engineering: Modifying AAV capsid proteins to enhance recognition of brain endothelial receptors
- Receptor targeting: Engineering vectors to exploit specific transport mechanisms at the BBB
- Bispecific conjugates: Developing molecular linkers that simultaneously bind the vector and BBB surface proteins
Lentiviral Vector Production
The company also manufactures HIV-based lentiviral vectors for ex vivo gene therapy approaches, particularly relevant for cell therapies where patient cells are modified outside the body before reinfusion.
Neurodegeneration Programs
ID Pharma's research efforts in neurodegeneration center on developing gene therapy approaches for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurological disorders:
Parkinson's Disease Programs
The company has active programs targeting Parkinson's disease through neurotrophic factor delivery[@gdnf_pd]:
| Program | Target | Development Stage | Delivery Approach |
|---------|--------|-------------------|-------------------|
| AAV-GDNF | Parkinson's disease | Preclinical | Intrastriatal injection |
| AAV-Neurturin | Parkinson's disease | Research | AAVrh10 serotype |
| AAV-ARTN | Parkinson's disease | Discovery | Engineered capsid |
Glial Cell Line-Derived Neurotrophic Factor (GDNF) delivery via AAV represents ID Pharma's most advanced program. GDNF is a potent neurotrophic factor that supports the survival and function of dopaminergic neurons in the substantia nigra pars compacta. Preclinical studies in non-human primate models have demonstrated that AAV-GDNF delivery can protect dopaminergic neurons from toxin-induced degeneration and promote regeneration of dopaminergic terminals.
Alzheimer's Disease Programs
Early-stage programs targeting Alzheimer's disease include:
- AAV-BDNF: Delivery of [brain-derived neurotrophic factor](/entities/bdnf) (BDNF) for support of cholinergic and hippocampal neurons
- AAV-NGF: Nerve growth factor delivery for basal forebrain cholinergic neuron survival
- Gene editing approaches: CRISPR-based strategies targeting disease-modifying genes
Manufacturing Capabilities
ID Pharma operates cGMP-compliant manufacturing facilities in Japan, providing end-to-end support from research-grade vectors to clinical trial material:
cGMP Production Facilities
- Vector production: Dedicated manufacturing suites for AAV and lentiviral production
- Purification: Multi-step chromatography purification (ion exchange, affinity, size exclusion)
- Quality control: Comprehensive testing including genome titer (ddPCR), purity (SDS-PAGE, AUC), potency (in vitro transduction assays), and safety (sterility, endotoxin, mycoplasma)
Quality Standards
| Standard | Scope | Application |
|----------|-------|-------------|
| cGMP (Japan) | PMDA compliance | Clinical trial material |
| ISO 13485 | Quality management | Medical device components |
| ICH Q5D | Cell substrate characterization | Production cell lines |
Strategic Partnerships
ID Pharma maintains partnerships with Japanese universities and international biotech companies to develop next-generation gene therapies[@japan_gt]. Key collaborators include:
- University of Tokyo: Neuroscience and virology research
- Kyoto University: iPSC and regenerative medicine applications
- Osaka University: CNS targeting and vector engineering
- National Center of Neurology and Psychiatry (NCNP): Clinical translation for movement disorders
The company provides vector manufacturing services to support clinical trials conducted by partner organizations, offering both research-grade and cGMP-produced vectors under AMED-funded programs[@amed_gt].
Market Position
Within Japan's gene therapy ecosystem, ID Pharma represents an essential infrastructure provider. While larger pharmaceutical companies have entered the AAV manufacturing field through acquisitions, ID Pharma maintains differentiation through:
Specialized neurological focus: Deep expertise in CNS-targeted vector design
Flexible manufacturing: Ability to produce small-batch clinical material for academic programs
Domestic production: Japanese-based manufacturing reduces supply chain risk for domestic pharmaceutical partners
Vector engineering capabilities: Proprietary serotype development and capsid modification expertiseSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
- [AAV Vectors for Neurodegenerative Gene Therapy](/therapeutics/aav-vectors-neurodegenerative-gene-therapy)